Navigation Links
Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Date:5/3/2012

e United States, Europe, Latin America and Asia have agreed to participate, providing the potential to identify meaningful information about regional or country-specific differences in patient demographics and treatment decisions.

Atrial fibrillation, characterized by an irregular heartbeat, can cause blood clots to form in the heart that can travel to the brain and cause a stroke. An estimated 2.3 million Americans are living with atrial fibrillation, and the prevalence is expected to increase to 5.6 million by 2050. Non-valvular atrial fibrillation, which accounts for up to 95 percent of diagnosed cases of atrial fibrillation, refers to cases of atrial fibrillation without rheumatic mitral valve disease, prosthetic heart valve or valve repair, according to the 2006 ACC/AHA/ESC guidelines. Atrial fibrillation increases the risk of stroke nearly five times and is associated with up to 15 percent of all strokes in the U.S. Atrial fibrillation imposes a substantial economic burden to the healthcare system, specifically the high costs associated with stroke.

In the pivotal RE-LY® trial, PRADAXA 150mg taken twice daily significantly reduced stroke and systemic embolism in patients with NVAF by 35 percent beyond the reduction achieved with warfarin dosed to target INR 2.0 to 3.0 (median TTR 67%). PRADAXA 150mg also was shown to significantly reduce both ischemic and hemorrhagic stroke compared to warfarin in patients with NVAF. Effects of PRADAXA compared to warfarin were more apparent in patients with lower levels of INR control.

*All trademarks are registered trademarks of their respective owners.

About Pradaxa® (dabigatran etexilate mesylate) Capsules

Indications and Usage

PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

IMPORTANT SAFETY INFORMATION ABOUT PRADAXA

'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)...  Boston Scientific Corporation (NYSE: BSX ) is ... long-term growth strategies at a meeting with the investment ... . President and Chief Executive Officer Mike Mahoney ... to bring forward meaningful innovation to transform patient care, ... value. "We are focused on addressing ...
(Date:5/1/2015)... 2015 Cambrex Corporation (NYSE: CBM ) reports ... Highlights , Sales increased 18% compared ... foreign currency impact, driven by Innovator products and Controlled Substances. ... in the first quarter of 2014. , GAAP Diluted ... first quarter last year and Adjusted Diluted EPS was $0.29 ...
(Date:4/30/2015)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its first quarter ended March ... first quarter of 2015 was $116.2 million, up $14.5 ... and down $5.3 million or 4.4% from the fourth ... income as reported in accordance with U.S. generally accepted ...
Breaking Medicine Technology:Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20
... Dec. 20, 2011  Advocates working with the disability and ... Senators and House members to help stop a Medicare ... wheelchairs prescribed by their physicians. Seven ... Medicare and Medicaid Services (CMS) for a prepayment review ...
... OSAKA, Japan, Dec. 20, 2011 Takeda Pharmaceutical ... Pharmaceuticals North America, Inc., announced today that the ... (azilsartan medoxomil and chlorthalidone) for the treatment of ... is the only fixed-dose therapy in the U.S. ...
Cached Medicine Technology:Michigan Seniors and Disabled Population Face Restricted Access to Power Wheelchairs Unless Congress Stops New Medicare Program 2Michigan Seniors and Disabled Population Face Restricted Access to Power Wheelchairs Unless Congress Stops New Medicare Program 3Michigan Seniors and Disabled Population Face Restricted Access to Power Wheelchairs Unless Congress Stops New Medicare Program 4FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 2FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 3FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 4FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 5FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 6FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 7
(Date:5/2/2015)... ProText Kinetic 2 is a set of typography ... X. ProText Kinetic 2 features 40 animation presets ... X . Easily create interactive text videos without having ... Kinetic 2. , Using ProText Kinetic is as easy as ... presets in the FCPX timeline. Playback the default animation ...
(Date:5/2/2015)... 2015 Kare Visits LLC. launched in Chicago ... caregivers. Kare Visits offers relief for caregivers by visiting ... According to the Caregiver Action Network, eight in ... 20 hours a week caring for an elderly or disabled ... hire a nurse, a caregiver is now empowered to schedule ...
(Date:5/1/2015)... May 02, 2015 The Venetian on ... http://www.thevenetiangracebay.com , and it is elegant and sophisticated, ... white and attractive turquoise hues of Grace Bay Beach. ... seven percent of leisure travelers used their smartphones throughout ... were used in the planning and researching and continued ...
(Date:5/1/2015)... Costa Mesa, CA (PRWEB) May 01, 2015 ... sponsor at the Cerner Southeast Regional User Group (RUG) ... 2015. The Cerner Southeast Regional User Group Conference provides ... access to vendors who support all aspects of electronic ... innovative use of Cerner software applications. , In addition ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 The Quail Creek ... American Cancer Society. Since 2001, the Quail Creek Relay team ... team host events throughout the year, including their biggest event, ... Golf Ball Drop. , Quail Creek Relay for Life ... battling cancer. Kate Kerwin, fitness director, states, “I was hooked ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2
... Federation of Clinical Immunology Services meeting in San Diego ... the disabling inflammatory condition. ,Dr. Gregersen ... in his laboratory at the Robert S. Boas Center ... for Medical Research in Manhasset, NY and more than ...
... then the "medical condition" on whose basis Paris Hilton was ... inside a day later, was not depression, but a sexually ... World paper, the heiress has contracted an STI, and it ... the Los Angeles' Century Regional Detention Center decided to remove ...
... researchers at San Francisco VA Medical Center (SFVAMC) has found ... can predict people who may develop dementia within six years. ... furnishes 87 per cent accurate results, is a 14-point index ... ,Lead study author Dr. Deborah E. Barnes, a mental ...
... scans and tests of reading skills when taken together are ... ,The study was conducted by a team of ... School of Medicine. , ,As part of the ... 12, who were identified as struggling readers, ran for a ...
... A new mechanistic description of how tumor cells migrate ... tumor metastasis has been developed by a swiss-based ... for developing anti-metastasis therapies. ,Scientists know that ... dont understand the details of how this deadly migration ...
... estimated 11,000 Filipino nurses re-sat their examinations Monday after ... their results, an official said Monday . Lawyers hired ... Schools (CGFNS) acted as observers at examination centres in ... Arturo Brion said the graduates were re-taking the examinations ...
Cached Medicine News:Health News:New Developments in Rheumatoid Arthritis 2Health News:New Developments in Rheumatoid Arthritis 3Health News:Paris' 'medical Condition' is a Sexually Transmitted Infection 2Health News:Simple Test to Predict People Who may Develop Dementia Within Six Years 2Health News:Combination of Brain Scans, Reading Skill Tests can Predict Kids Reading Problems 2Health News:Developing Antimetastasis Therapy- An Early Stage of Tumor Control. 2Health News:Philippine Nurses Re-sit Scandal-tainted Exams 2
... Finnpipette Focus multichannel pipettes ... of reagents into microplates, ... 0.1-10 l volumes. The ... Finnpipette Focus multichannels, combined ...
... Research pro Electronic Pipette is ideal for ... Its easy-to-follow display, ergonomically-placed operating buttons, and ... reverse pipetting and diluting make this a ... functions of a manual pipette without any ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
... best value in high performance electronic pipetting!, ... design reduce hand fatigue and strain , ... ejector , Color coding for easy volume ... greater performance use Hamilton AdvanTip Low Retention ...
Medicine Products: